These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26732521)

  • 1. Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide.
    Bouledjouidja A; Masmoudi Y; Van Speybroeck M; Schueller L; Badens E
    Int J Pharm; 2016 Feb; 499(1-2):1-9. PubMed ID: 26732521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
    Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
    Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fenofibrate-mesoporous silica drug-loading processes for enhanced drug delivery.
    Ahern RJ; Hanrahan JP; Tobin JM; Ryan KB; Crean AM
    Eur J Pharm Sci; 2013 Nov; 50(3-4):400-9. PubMed ID: 23981335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide.
    Sanganwar GP; Gupta RB
    Int J Pharm; 2008 Aug; 360(1-2):213-8. PubMed ID: 18550302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs.
    Bukara K; Schueller L; Rosier J; Daems T; Verheyden L; Eelen S; Martens JA; Van den Mooter G; Bugarski B; Kiekens F
    J Pharm Sci; 2016 Aug; 105(8):2381-5. PubMed ID: 27364460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impregnation of mesoporous silica with poor aqueous soluble molecule using pressurized carbon dioxide: Is the solubility in the supercritical and subcritical phase a critical parameter?
    Koch N; Jennotte O; Grignard B; Lechanteur A; Evrard B
    Eur J Pharm Sci; 2020 Jul; 150():105332. PubMed ID: 32361178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of supercritical carbon dioxide (SC-CO2) processing conditions on drug loading and physicochemical properties.
    Ahern RJ; Crean AM; Ryan KB
    Int J Pharm; 2012 Dec; 439(1-2):92-9. PubMed ID: 23041132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability.
    Niu X; Wan L; Hou Z; Wang T; Sun C; Sun J; Zhao P; Jiang T; Wang S
    Int J Pharm; 2013 Aug; 452(1-2):382-9. PubMed ID: 23688621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loading amorphous Asarone in mesoporous silica SBA-15 through supercritical carbon dioxide technology to enhance dissolution and bioavailability.
    Zhang Z; Quan G; Wu Q; Zhou C; Li F; Bai X; Li G; Pan X; Wu C
    Eur J Pharm Biopharm; 2015 May; 92():28-31. PubMed ID: 25720818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution Improvement of Progesterone and Testosterone via Impregnation on Mesoporous Silica Using Supercritical Carbon Dioxide.
    Ajiboye AL; Jacopin A; Mattern C; Nandi U; Hurt A; Trivedi V
    AAPS PharmSciTech; 2022 Nov; 23(8):302. PubMed ID: 36385204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing in vitro dissolution and in vivo bioavailability of fenofibrate by solid self-emulsifying matrix combined with SBA-15 mesoporous silica.
    Quan G; Wu Q; Zhang X; Zhan Z; Zhou C; Chen B; Zhang Z; Li G; Pan X; Wu C
    Colloids Surf B Biointerfaces; 2016 May; 141():476-482. PubMed ID: 26896653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
    Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
    Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation.
    Pestieau A; Krier F; Lebrun P; Brouwers A; Streel B; Evrard B
    Int J Pharm; 2015 May; 485(1-2):295-305. PubMed ID: 25796121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
    O'Shea JP; Nagarsekar K; Wieber A; Witt V; Herbert E; O'Driscoll CM; Saal C; Lubda D; Griffin BT; Dressman JB
    J Pharm Pharmacol; 2017 Oct; 69(10):1284-1292. PubMed ID: 28631822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica.
    Van Speybroeck M; Mellaerts R; Mols R; Thi TD; Martens JA; Van Humbeeck J; Annaert P; Van den Mooter G; Augustijns P
    Eur J Pharm Sci; 2010 Dec; 41(5):623-30. PubMed ID: 20850527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
    Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
    Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
    Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
    J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation.
    Sayed E; Karavasili C; Ruparelia K; Haj-Ahmad R; Charalambopoulou G; Steriotis T; Giasafaki D; Cox P; Singh N; Giassafaki LN; Mpenekou A; Markopoulou CK; Vizirianakis IS; Chang MW; Fatouros DG; Ahmad Z
    J Control Release; 2018 May; 278():142-155. PubMed ID: 29605567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man.
    Bukara K; Schueller L; Rosier J; Martens MA; Daems T; Verheyden L; Eelen S; Van Speybroeck M; Libanati C; Martens JA; Van Den Mooter G; Frérart F; Jolling K; De Gieter M; Bugarski B; Kiekens F
    Eur J Pharm Biopharm; 2016 Nov; 108():220-225. PubMed ID: 27648957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable and Fast-Dissolving Amorphous Drug Composites Preparation via Impregnation of Neusilin
    Azad M; Moreno J; Davé R
    J Pharm Sci; 2018 Jan; 107(1):170-182. PubMed ID: 29031953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.